Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Sep 25, 2026
Why Is Tradr 2X Long BE Daily ETF (BEX) Up +18.84% Today?

Why Is Tradr 2X Long BE Daily ETF (BEX) Up +18.84% Today?

Key Takeaways

  • BEX jumped +18.84% on September 25, 2026, to $41.12 from a prior close of $34.60.
  • The surge mirrors a sharp rebound in underlying holding Bloom Energy, which rallied roughly 9.4% intraday.
  • The primary catalyst was a recovery from Thursday's selloff after Oracle and project developer Blue Owl reaffirmed the Project Jupiter data-center timeline.
  • Bullish analyst commentary and elevated call-option activity reinforced the upside move.
  • As a leveraged single-stock fund, BEX amplifies daily moves in Bloom Energy by roughly 2x, magnifying both gains and losses.
  • Investors are watching execution on the Oracle fuel-cell deployment and upcoming Q3 earnings scheduled for late October.

Opening Summary

The Tradr 2X Long BE Daily ETF (BEX) provides daily leveraged exposure, targeting approximately two times the daily performance of Bloom Energy. On September 25, 2026, the fund climbed +18.84% to $41.12, up from a previous session close of $34.60, confirming a sharply higher move. The advance tracked a rebound in Bloom Energy, which recovered roughly 9.4% intraday as investor concerns tied to Oracle's Project Jupiter data-center campus eased and reassurances from all parties stabilized sentiment.

What Drove the ETF Move Today

A Rebound in Underlying Holding Bloom Energy

Because BEX is a 2x leveraged single-stock fund, its price action is driven almost entirely by Bloom Energy. After declining on Thursday on reports that Oracle had issued a force majeure notice tied to the Project Jupiter data center in New Mexico, Bloom Energy rebounded sharply on Friday. Oracle reiterated that the project remains on its planned schedule, while Blue Owl Capital, the site's developer, said the notice does not alter the financial commitments of the parties involved. That reassurance prompted traders who had sold into Thursday's headline to re-enter, fueling the bounce.

AI Data-Center Power Demand Remains Intact

The recovery also reflects the broader investment thesis behind Bloom Energy: surging electricity demand from AI data centers. Bloom's solid-oxide fuel cells offer on-site power generation that can be deployed far faster than grid connections, positioning the company as a key beneficiary of hyperscaler buildouts. The Project Jupiter deployment, which calls for up to 2.45 gigawatts of Bloom capacity, is a central part of that narrative, and confirmation that the timeline is intact removed a key near-term overhang.

Analyst Support and Bullish Options Flow

Supportive analyst commentary added to the upside. Morgan Stanley's David Arcaro maintained a Buy rating and a $310 price target on Bloom Energy, describing Oracle's force majeure notice as a risk-management formality rather than a signal the customer was pulling back. Separately, options activity leaned bullish, with call volume running about twice normal levels and the put/call ratio near 0.54, indicating traders were positioning for further upside.

Which Holdings Contributed Most

BEX is a single-stock leveraged ETF, meaning its exposure is concentrated in Bloom Energy through derivatives and swap instruments rather than a diversified basket of securities. As a result, Bloom Energy alone accounted for essentially the entire move. The underlying stock's roughly 9.4% intraday gain, amplified by the fund's 2x daily leverage objective, translated into the approximately 18.8% advance in BEX. This concentration is the defining feature of the fund: it offers magnified exposure to one high-beta name, with no diversification from other holdings.

Market Context and Trading Activity

The move occurred during the regular trading session and was directionally consistent with the performance of the underlying security. Trading in leveraged single-stock ETFs tends to be elevated during sharp swings in the reference stock, as traders use these vehicles for short-term tactical exposure. The rebound followed a period of heightened volatility in Bloom Energy, which had rallied more than 200% year-to-date amid AI-power demand before pulling back on the Project Jupiter headlines. Broader equity market moves played a limited role; the advance was primarily company-specific rather than a broad sector-driven rotation.

What Comes Next for BEX

Investors should monitor several factors that could shape BEX's near-term trajectory. First, execution on the Oracle Project Jupiter deployment and any updates on its air-quality permitting and natural-gas pipeline timeline will be closely watched. Second, Bloom Energy's third-quarter earnings, expected in late October, will test whether the company's accelerating revenue growth and raised full-year guidance remain on track. Third, broader sentiment toward AI data-center power demand will continue to influence the stock's multiple.

It is important to note that BEX is designed for daily holding periods. The effects of daily leverage reset and compounding mean the fund's returns over longer periods can diverge significantly from two times the underlying stock's cumulative return, particularly in volatile markets. Investors should weigh these risks carefully.

Trending AI Robots

Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in the curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, giving traders a way to explore systematic approaches tailored to different market environments. Explore the Trending AI Robots page to see which automated strategies are currently leading the market.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: BEX

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


Momentum Indicator for BEX turns positive, indicating new upward trend

BEX saw its Momentum Indicator move above the 0 level on September 23, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 14 similar instances where the indicator turned positive. In 14 of the 14 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

BEX moved above its 50-day moving average on September 04, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for BEX crossed bullishly above the 50-day moving average on September 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 1 of 2 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 50%.

Following a +8.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where BEX advanced for three days, in 43 of 44 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

The Aroon Indicator entered an Uptrend today. In 45 of 45 cases where BEX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.

Bearish Trend Analysis

The 10-day RSI Indicator for BEX moved out of overbought territory on September 09, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 6 similar instances where the indicator moved out of overbought territory. In 6 of the 6 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 10 of 10 cases where BEX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BEX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

BEX broke above its upper Bollinger Band on September 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Industry description

The investment seeks daily investment results, before fees and expenses, that correspond to two times (200%) the daily performance of the common shares of Bloom Energy Corporation. Under normal market circumstances, the fund will maintain at least 80% exposure to financial instruments that provide two times leveraged exposure to the daily performance of BE. This may include BE stock in addition to financial instruments. The fund is non-diversified.
View a ticker or compare two or three
BEX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Category Trading

Category
Trading--Leveraged Equity
Address
Investment Managers Series Trust II803 West Michigan StreetMilwaukee
Phone
(414) 299-2295
Web
N/A
Interact to see
Advertisement
INSM shares are surging approximately +10% in premarket trading on Monday, March 23, 2026, from a prior close of $136.00, placing the premarket price near $149.60. The primary catalyst is the release of positive topline results from the Phase 3 ENCORE trial of ARIKAYCE® in patients with newly diagnosed or recurrent MAC (Mycobacterium avium complex) lung disease — a readout Insmed had flagged as expected in "March or April 2026".
CF shares are trading approximately -6% lower in Monday's premarket session, dropping from a Friday close of $124.90 to approximately $117.41. Primary catalyst: President Trump announced a five-day pause on strikes against Iranian energy infrastructure following "very good" diplomatic signals, triggering a sharp unwind of the geopolitical risk premium embedded in fertilizer stocks.
APGE shares surged approximately 16% in premarket trading on March 23, 2026, after the company announced positive 52-week data from Part A of its Phase 2 APEX clinical trial. The primary catalyst is a highly anticipated clinical readout showing that zumilokibart (APG777) delivered durable and deepening responses in patients with moderate-to-severe atopic dermatitis at both every 3-month and 6-month dosing intervals.
Shares of VALN are plummeting approximately 35% in Monday's session, from a Friday close of $10.66 to roughly $6.93, in heavy volume trading. The primary catalyst is the release of Phase 3 VALOR trial topline results for Valneva's Lyme disease vaccine candidate, co-developed with PFE (Pfizer) — results that showed strong clinical efficacy but failed to meet the pre-determined statistical criterion for the primary endpoint.
AXTI is surging approximately +11.00% in Monday's session, trading near $60.21, up from a prior closing price of $54.24. The move extends the stock's post-earnings rally that began last Thursday when shares jumped more than 19% following AXT's Q4 2025 results.
Tower Semiconductor (TSEM) shares are surging approximately +10% intraday on Monday, March 23, trading around $180, up from the previous close of $163.63 on March 20, 2026. The primary catalyst is the opening day of APEC 2026 in San Antonio, Texas, where Tower Semiconductor is presenting its newly unveiled Gen3 BCD power management platform designed to address escalating AI data center power demands.
CD is indicated down about 17% in premarket trading after the latest completed session, pointing to a sharp negative market reaction heading into the open. The stock’s weakness comes against a backdrop of lingering uncertainty following its privatization and delisting process from Nasdaq, which has left limited liquidity and a thinner news flow around the name.
SEDG is indicated down roughly 9% in premarket trading, following a strong advance in the prior regular session. The pullback comes after shares rallied on optimism around new product launches and an analyst upgrade, leaving the stock vulnerable to profit-taking and volatility.
NTGR shares surged approximately 11% in premarket trading on March 24, 2026, building on a roughly 20% overnight jump in the prior session. The primary catalyst is a landmark Federal Communications Commission (FCC) ruling that prohibits all imports of consumer routers manufactured overseas, citing national security concerns.
ANNA is surging approximately +20.00% in Tuesday's premarket session, rebounding sharply from Monday's -22.84% decline. The primary catalyst remains the ongoing U.S.-Iran military conflict, which disrupted Qatari LNG exports and drove European benchmark natural gas prices to multi-year highs.
Concentrix Corporation (CNXC) shares are falling approximately 11% in Tuesday's premarket session after the company released its fiscal Q1 2026 earnings report before market open. Adjusted diluted EPS came in at $2.61, missing the Wall Street consensus estimate of approximately $2.64.
Shares of Karyopharm Therapeutics (KPTI) are trading approximately 12% lower in Tuesday's premarket session, with the previous close at $7.63. The primary catalyst is the March 24 release of topline Phase 3 SENTRY trial data, in which the company met only one of two co-primary endpoints.
IBRX shares are down approximately 23% in Tuesday's session, trading near $7.24 after closing at $9.40 on Monday, March 23. The sharp decline follows an 11%+ surge in the prior session, with profit-taking and valuation pressure cited as primary triggers.
Shares of Circle Internet Group (CRCL) are down approximately 9% in Tuesday morning trading, extending a pullback from recent multi-month highs above $126. The primary catalyst appears to be a broad crypto-sector risk-off wave, with Bitcoin sliding below $69,000 and the Fear & Greed Index dropping to extreme fear territory.
ALM shares are indicated down about 11% in early Tuesday trading after closing the prior session at $16.93. The move comes after a powerful multi‑month rally that took the stock from below $3 to an intraday high of $22.55 earlier in March, leaving it vulnerable to profit-taking and volatility.​
LUNR shares are indicated down about 7% in Tuesday premarket trading after closing the last regular session at $20.31. The pullback follows a powerful rally driven by strong 2026 revenue guidance of $900 million–$1 billion and upbeat analyst commentary, including price target hikes and buy ratings.
MAZE shares are trading approximately 27% lower in premarket on March 25, 2026, after the company reported its highly anticipated Phase 2 HORIZON trial topline data for lead drug candidate MZE829. The catalyst is a dual announcement: Phase 2 clinical data for MZE829 in APOL1-mediated kidney disease (AMKD) alongside Q4 and full-year 2025 financial results.
ARM shares surged approximately +10% in premarket trading on March 25, 2026, hitting $148.6 from a prior close of approximately $135. The primary catalyst is Arm's historic strategic pivot: the company announced it will begin selling its own self-developed AGI CPU chips, breaking its decades-long "IP licensing only" business model.
Shares of Enliven Therapeutics (ELVN) are surging approximately +15% in premarket trading on March 25, 2026, driven by renewed investor enthusiasm around the company's advancing clinical program for ELVN-001 in chronic myeloid leukemia (CML). The stock's prior closing price on March 24, 2026 was $31.15, placing the premarket indicated price near $35.82.
AVXL shares are down approximately 29% in premarket trading on Wednesday, March 25, 2026, falling to roughly $2.97 from the prior close of $4.19. The primary catalyst is Anavex's formal withdrawal of its marketing authorization application (MAA) for blarcamesine from the European Union, announced in the early hours of March 25, 2026.
Why Is Tradr 2X Long BE Daily ETF (BEX) Up +18.84% Today?